Ms. Holland is a member of AIPLA, NYIPLA and the Federal Circuit Bar Association.
Ms. Holland has successfully represented companies such as Teva, Actavis, Lupin, Sun, Ceva Sante, Enzymotec, Celltrion and Boston Scientific in patent litigation in district courts throughout the United States, at the International Trade Commission, in post-grant proceedings before the PTAB, and at the Federal Circuit. Ms. Holland has also coordinated worldwide patent litigation, and has particular experience with courts in the U.K., Netherlands, France, Israel, India and Mexico.
Ms. Holland’s significant victories include:
- Wins in S.D.N.Y. (after trial), Federal Circuit and U.S. Supreme Court in consolidated patent litigations concerning the drug Copaxone®.
- Wins in D.N.J. (after trial) and Federal Circuit in patent litigation concerning the drug Atelvia®.
- Win in D.N.J. (defeated TRO and PI motions) in patent litigation concerning the drug Abilify®. Achieved subsequent favorable settlement.
- Wins in S.D. Ind. (after trial) and Federal Circuit in patent litigation concerning the drug Gemzar®.
- Win in D. Mass. (after trial) in patent litigation concerning the drug Relafen®. Achieved favorable settlement while on appeal.
- Wins in D. Del. (on summary judgment) and Federal Circuit in patent litigation concerning coronary stents.
- Wins in S.D.N.Y. (on summary judgment) and Federal Circuit in patent litigation concerning pertussis vaccines.
- Win in D.N.J. in a false advertising case concerning x-ray contrast agents.
Ms. Holland has also achieved numerous favorable settlements on behalf of clients.
Prior to joining Goodwin in 2014, Ms. Holland was a partner at Kenyon & Kenyon in New York City, where she chaired its Diversity Committee and was the first woman to serve on its Management Committee. She previously practiced at Paul Weiss, where she litigated a variety of cases, including patent infringement, securities, real estate and contract matters.